tbuckley/cabot-search huggingface dataset:
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial
Authors: Pieter Sonneveld, Hans-Juergen Salwender, Bronno Van Der Holt, Laila el Jarari, Uta Bertsch, Igor W. Blau, Sonja Zweegman, Katja C. Weisel, Edo Vellenga, Michael Pfreundschuh, Annemiek Broijl, Christof Scheid, Shulamiet Wittebol, Gerard M.J. Bos, Marjan Stevens-Kroef, Anna Jauch, Anna Potamianou, Dirk Hose, Reinier Raymakers, Marinus Schaafsme, Marie Jose Kersten, Marinus van Marwijk Kooy, Ulrich Duehrsen, Hans Walter Lindemann, Peter Brossart, Pierre Wijermans, Henk M. Lokhorst, Hartmut Goldschmidt
Journal: Blood (2015)
Serum Levels of B-Cell Maturation Antigen Are Elevated in Multiple Myeloma Patients and Correlate with Disease Status and Overall Survival
Authors: Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy S Wang, Danielle Rauch, Kevin Delijani, Kevin DeCorso, Andrew Prajogi, Haiming Chen, James R. Berenson
Journal: Blood (2012)
Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.
Authors: Anas Younes, Peter McLaughlin, Luis E. Fayad, Andre Goy, Jorge E. Romaguera, Barbara Pro, Maria A. Rodriguez, Felipe Samaniego, Larry Kwak, Sattva Neelapu, Jeffrey Medeiros
Journal: Blood (2005)
Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?
Authors: Elisavet Chatzilari, Panagiotis Baliakas, Aliki Xochelli, Anastasios Maronidis, Anna Vardi, Mattias Mattsson, Karin Larsson, Vassiliki Douka, Michail Iskas, George Karavalakis, Apostolia Papalexandri, Carsten Niemann, Marco Montillo, Achilles Anagnostopoulos, David Oscier, Sarka Pospisilova, Frederic Davi, Niki Stavroyianni, Paolo Ghia, Anastasia Hadzidimitriou, Richard Rosenquist, Spiros Nikolopoulos, Kostas Stamatopoulos, Yannis Kompatsiaris
Journal: Blood (2015)
GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis
Authors: Aditya A. Joshi, Joseph B. Lerman, Tsion M. Aberra, Mehdi Afshar, Heather L. Teague, Justin A. Rodante, Parasuram Krishnamoorthy, Qimin Ng, Tarek Z. Aridi, Taufiq Salahuddin, Balaji Natarajan, Benjamin N. Lockshin, Mark A. Ahlman, Marcus Y. Chen, Daniel J. Rader, Muredach P. Reilly, Alan T. Remaley, David A. Bluemke, Martin P. Playford, Joel M. Gelfand, Nehal N. Mehta
Journal: Circulation Research (2016)

GlycA, an emerging inflammatory biomarker, predicted cardiovascular events in population-based studies. Psoriasis, an inflammatory disease associated with increased cardiovascular risk, provides a model to study inflammatory biomarkers in cardiovascular disease (CVD). Whether GlycA associates with psoriasis and how it predicts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown.To investigate the relationships between GlycA and psoriasis and between GlycA and subclinical CVD.Patients with psoriasis and controls (n=412) participated in a 2-stage study. We measured GlycA by nuclear magnetic resonance spectroscopy. National Institutes of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG PET/CT) scans to assess vascular inflammation (VI) and coronary computed tomographic angiography to quantify coronary artery disease burden. Psoriasis cohorts were young (mean age=47.9), with low cardiovascular risk and moderate skin disease. high-sensitivity C-reactive protein and GlycA were increased in psoriasis compared with controls (GlycA: [PENN: 408.8±75.4 versus 289.4±60.2, P<0.0001; NIH: 415.8±63.2 versus 346.2±46, P<0.0001]) and demonstrated a dose-response with psoriasis severity. In stage 2, VI (β=0.36, P<0.001) and coronary artery disease (β=0.29, P=0.004) associated with GlycA beyond CV risk factors in psoriasis. In receiver operating characteristic analysis, GlycA added value in predicting VI (P=0.01) and coronary artery disease (P<0.01). Finally, initiating anti-tumor necrosis factor therapy (n=16) reduced psoriasis severity (P<0.001), GlycA (463.7±92.5 versus 370.1±78.5, P<0.001) and VI (1.93±0.36 versus 1.76±0.19, P<0.001), whereas GlycA remained associated with VI (β=0.56, P<0.001) post treatment.GlycA associated with psoriasis severity and subclinical CVD beyond traditional CV risk and high-sensitivity C-reactive protein. Moreover, psoriasis treatment reduced GlycA and VI. These findings support the potential use of GlycA in subclinical CVD risk assessment in psoriasis and potentially other inflammatory diseases.
Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Authors: Boglarka Gyurkocza, Jonathan Gutman, Eneida R. Nemecek, Eileen Sickle, Merav Bar, Joachim Baumgart, Colleen Delaney, Barry Storer, Frederick R. Appelbaum, H. Joachim Deeg
Journal: Blood (2012)
Acute Splenic Sequestration In a Newborn Cohort with Sickle Cell Anemia (SCA): Predictive Factors and Impact on Disease Severity
Authors: Cécile Arnaud, Annie Kamdem, Lena Coïc, Nadia Médejel, Emmanuelle Lesprit, Isabelle Hau, Fouad Madhi, Sophie Lemerle, Sandra Biscardi, Francoise Bernaudin
Journal: Blood (2010)
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
Authors: K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Löw, M Binder, J Atta, U Keller, H-H Wolf, S W Krause, G Heß, R Naumann, S Sasse, C Hirt, M Lamprecht, U Martens, A Morgner, J Panse, N Frickhofen, A Röth, C Hader, M Deckert, H Fricker, G Ihorst, J Finke, G Illerhaus
Journal: Leukemia (2016)

To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m2, days 1, 15, 29), high-dose methotrexate (3 g/m2 days 2, 16, 30), procarbazine (60 mg/m2 days 2–11) and lomustine (110 mg/m2, day 2)—R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less ⩾grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.
Kinetics Of Low-Level Mutant Clones Detected By Subcloning and Sequencing In Tyrosine Kinase Inhibitor Resistant CML
Authors: Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Yun Jeong Oh, Jin-Eok Park, Hae Lyun Yoo, Hye-Rim Jeon, Eun-Jung Jang, Dong-Wook Kim
Journal: Blood (2013)
AB0886 A Quality of Life (QOL) Study of 100 Children with Juvenile Idiopathic Arthritis (JIA) from Northern India: Table 1.
Authors: M. Agarwal, S. Sawhney, S. Mittal
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> JIA affects many domains of a child9s life. The patient with JIA has a lot to cope with: Physical pain, medicine intake (both parenteral and oral), clinic appointments, phlebotomy, exclusion from school and social activities during disease flares and anxiety about disease.JIA has an impact on the child9s physical, mental and psychosocial health. There is a lacuna in the assessment of Pediatric QoL in these children from our country,we thus undertook this study. <h3>Objectives</h3> 1) To assess the QoL score of JIA patients using i) Pediatric rheumatology quality of life (PRQL) score [1] and ii) Pediatric quality of life 3.0 rheumatology module(PedsQL) score [2]. 2) To assess the clinical and socioeconomic factors that may impact the QoL. 3) To correlate PRQL and PedsQL <h3>Methods</h3> 100 consecutive children with JIA, 2–18 yr,attending Ped rheumatology unit during a 8 week period were evaluated for QoL. PRQL (parent &amp; child version) PedsQL (parent &amp; child version) &amp; CHAQ (Childhood Health Assessment Questionaire) [3] were completed. Entry criteria was JIA patients with at least 6 months of disease. <h3>Results</h3> 46 girls &amp; 54 boys with a median age of 11 yrs (2–18 yrs). Median age:6.2 yrs at disease onset,7.62yrs at diagnosis. 28 children had clinically active disease on the day of QoL assessment. Age:2–4 yr:8, 5–7 yr.:18, 8–12 yr.:35 and 13–18 yr.:39.Diagnosis: SOJIA: 31,ERA: 42,PJIA:14,OJIA:13.Socio economic indicators: Mother9s literacy status: Unlettered 4,primary schooling 10,High school 12,Senior school 7,Graduates 37,Post graduates 30.Stay at home mothers:85,working 15. 19 children belonged to lower socioeconomic strata. Children with clinically active disease had poorer QoL as compared to clinically inactive group (Mann-Whitney test: p&lt;0.00).QoL indicators and CHAQ had no statistical correlation. PRQL and PedsQL were in agreement with each other (Spearman9s rho,r=0.72) and both parent and child versions were in concordance. <h3>Conclusions</h3> Both PRQL and PedsQL are appropriate tools to assess QOL in JIA. Clinical disease activity status impacts QoL adversely.There was no difference in QoL of children from various socioeconomic strata, nor did the parental education or professional status impact it. <h3>References</h3> Weiss PF et al. The pediatric rheumatology QoL scale: validation of the English version in a US cohort of JIA. PROJ.2013;11:43 Varni JWet al.The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the pediatric QoL inventory generic core scales and rheumatology module. Arthritis Rheum. 2002;46 (3):714–725 Dempster H et al. The clinical meaning of functional outcome scores in children with juvenile arthritis.Arthritis Rheum. 2001;44(8):1768–74 <h3>Disclosure of Interest</h3> None declared
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
Authors: Jorge E Cortes, Carmino Antonio De Souza, Manuel Ayala, Jose Luis Lopez, Eduardo Bullorsky, Sandip Shah, Xiaojun Huang, K Govind Babu, Kudrat Abdulkadyrov, José Salvador Rodrigues de Oliveira, Zhi-Xiang Shen, Tomasz Sacha, Israel Bendit, Zhizhou Liang, Tina Owugah, Tomasz Szczudlo, Sadhvi Khanna, Rafik Fellague-Chebra, Philipp D le Coutre
Journal: The Lancet Haematology (2016)
Optimizing Results of Unrelated Donor Hematopoietic Stem Cell Transplantion in Developing Countries: Young Age and Early Disease as Positive Factors for Survival.
Authors: Vaneuza A.M. Funke, Elenaide C. Nunes, Eliane Cezario, Jefferson Ruiz, Daniela C. Setubal, Michel M. Oliveira, Carmem M.S. Bonfim, Marco A. Bitencourt, Claudia Pettengil, Larissa Medeiros, Heliz Regina A. Neves Datamager, Jose Zanis Neto, Carlos R. Medeiros, Ricardo Pasquini
Journal: Blood (2006)
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer
Authors: David R. Gandara, Natasha Leighl, Jean-Pierre Delord, Fabrice Barlesi, Jaafar Bennouna, Gerald Zalcman, Jeffrey R. Infante, Karen L. Reckamp, Karen Kelly, Frances A. Shepherd, Julien Mazieres, Filip Janku, Olivia S. Gardner, Bijoyesh Mookerjee, Yuehui Wu, Donna S. Cox, Dan Schramek, Vijay Peddareddigari, Yuan Liu, Anthony M. D'Amelio, George Blumenschein
Journal: Journal of Thoracic Oncology (2016)
FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation
Authors: Tomasz Sewastianik, Maciej Szydlowski, Emilia Bialopiotrowicz, Ewa Jablonska, Przemyslaw Kiliszek, Anna Polak, Monika Prochorec-Sobieszek, Anna Szumera-Cieckiewicz, Tomasz S. Kaminski, Patryk Gorniak, Sergiusz Markowicz, Eliza Nowak, Monika A. Grygorowicz, Krzysztof Warzocha, Przemyslaw Juszczynski
Journal: Blood (2015)
FRI0634-HPR Complex Treatement of Patients with Gouty Arthritis
Authors: N.G. Nikolov, M.S. Krastanova, M.S. Panchovka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is a type of arthritis caused by the formation of uric acid crystals within or around the joints. It is the most common type of inflammation arthritis for people over 40. For some of the patients, the leading symptoms are pain and stiffness in the joints, while others develop heavy joint deformations and permanent disabilities. Applying a complex rehabilitation approach with rheumatologic aid and a physio-rehabilitation program significantly improves the condition of the patients with gouty arthritis, the strength of their symptoms diminishes, and becoming handicapped is avoided or significantly delayed. <h3>Objectives</h3> The aim of this study is to measure the effect of conducting a complex drug treatment combined with a physio-rehabilitation program in patients with gouty arthritis in an acute or chronic stage that heavily affects the musculoskeletal system. <h3>Methods</h3> Between 2013 and 2015, 39 patients with gouty arthritis were hospitalized and treated at the Rheumatology Ward at UMHAT “Dr. Georgi Stranski” – Pleven. 26 of them were male and 13 female, aged between 43 and 62 years old, in subacute or chronic stage (SUE &lt;25 mm, fibrinogen and CRP at relevant values, AST and RF (−). In addition to the drug therapy with analgesics, NSAIDs and chondoprotectors, uricoinhibitors and urikoeliminators during the non-paroxysmal period, the patients also undergo a complex physical and rehabilitation program consisting of: electrotherapy (magnetic field, mid-frequency currents and ultrasound therapy with NSAIDs, therapeutic massages, cryotherapy, active methods of kinesitherapy and occupational therapy. Functional tests and measurements – VAS for the pain, a daily activities life test (DAL) and complex functional assessment test (CFA) – were made for the purpose of the study at the beginning and at the end of the observed period. <h3>Results</h3> An individual file was created for every patient where the results from the tests and measurements are stored in order to track the patient9s condition over the course of treatment. The treatment consists of 3 stages: a period in the Rheumatology ward, treatment in the Medical Rehabilitation ward and ambulatory physio-rehabilitation courses. Conducting physiotherapeutic treatment for patients with gouty arthritis in an acute or chronic stage complements the drug treatment and leads to faster relief of the symptoms during an acute stage, decreases the timeframe of the temporary inability to work, prevents any permanent damage to the affected joints and prevents the occurrence of permanent disabilities. <h3>Conclusions</h3> For patients with gouty arthritis in an acute or chronic stage that heavily affects the musculoskeletal system, the complex physio-rehabilitational and rheumathological treatment is effective and leads to a significant improvement in the quality of life of the patients. <h3>Disclosure of Interest</h3> None declared
Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin
Authors: Amin N Alpesh, Allison Keshishian, Lin Xie, Onur Baser, Kwanza Price, Lien Vo, Prianka Singh, Amanda Bruno, Jack Mardekian, Wilson Tan, Shalabh Singhal, Chad Patel, Kevin Odell, Jeffrey Trocio
Journal: Blood (2015)
Transgenic Expression of IL15 Selectively Expands Antigen Specific Cytotoxic T Cells (CTLs) Enhancing Their Anti-Tumor Effect In Vivo.
Authors: J. Vera, C. Quintarelli, B. Savoldo, G. Giordano, A. Foster, M. Pule, Helen Heslop, C. Rooney, Malcolm Brenner, G. Dotti
Journal: Blood (2006)
PTH-153 The Impact of an Open Access, Non-Face to Face Nurse Led Inflammatory Bowel Disease Service on Service Transformation and Patient Outcomes
Authors: RC Reynolds, C Bull, K Street, K Railton, M Ragheb, P Kerr, A Taylor Gonzales, AR Ansari
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD) follows an unpredictable clinical course, adversely affecting quality of life for many patients. Access to specialist IBD services is necessary in addition to routine review in the outpatient setting, when patients are often stable. Accessing these services is a considerable source of frustration amongst IBD patients. Due to the complex nature of IBD management GPs now play a relatively minor role, however often become the first point of contact. It is widely acknowledged that patients value access to specialist services. IBD specialist nurses are invaluable in providing continuity of care and bridging the gap to multidisciplinary secondary care services. By providing an open access, non-face to face nurse led IBD service, we are able to use our dataset to inform and commission service transformation and improve patient outcomes. <h3>Methods</h3> Data was extracted from a comprehensive dataset of unrestricted non-face to face interactions. This was taken from consecutive patients over a 12 month period for immunosuppression monitoring and a consecutive 3 month sample for all other data. <h3>Results</h3> The total number of consecutive contacts with the service in 12 months in the year 2015 was 4358, rising from 3000 contacts in 2014. Monitoring of immunosuppressive treatment constituted the greatest workload with 1500 contacts in 12 months from 450 patients. In a 3 month period, provision of our service avoided 20 hospital admissions, 34 accident and emergency department attendances and 110 outpatient appointments. We supported patients by issuing 120 prescriptions, organising 24 procedures, 22 multidisciplinary discussions and 12 urgent surgical reviews. This was achieved via 1600 emails, 1400 telephone calls and 1000 contacts from 400 patients using the 'Patient Knows Best' software, in a 12 month period. <h3>Conclusion</h3> Our dataset has enabled analysis of the workflow of an open access non-face to face service. The volume of workload demonstrates that patients highly value this form of support. The flexibility of the service has diverted pressure of immunosuppressive monitoring away from busy consultant clinics. This data has helped to inform service transformation by allowing costing on new local tariffs for non-face to face appointments. Contacts are currently tariffed at £25, regardless of time invested, value added or outcome. In the past, this has been a disincentive to seeing IBD follow ups in comparison to the tariffs attracted for new patient workflow. We estimate the tariff for each contact with the non-face to face service to be £60. <h3>Disclosure of Interest</h3> None Declared
Pathologic Stages IA and IIA Hodgkin's Disease
Authors: Samuel Hellman
Journal: Journal of Clinical Oncology (1985)

In the editorial by Samuel Hellman "Pathologic Stages IA and IIA Hodgkin's Disease: Results of Treatment With Radiotherapy Alone, 1968–1980" (Journal of Clinical Oncology 3:749–750, 1985), an error was made that altered the meaning of a sentence. The correct sentence appears below. As long as such change is the case, there is justification for exposing the patient to the morbidity and, on rare occasions, the mortality of this procedure.
Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.
Authors: Christoph Driessen, Jeanette Gogel, Marianne Kraus, Huib Ovaa, Alexander Beck, Thomas Rückrich
Journal: Blood (2005)
Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
Authors: Jacalyn Rosenblatt, Irit Avivi, Baldev Vasir, Lynne Uhl, Tami Katz, Poorvi Somaiya, Heidi Mills, Robin Joyce, James D. Levine, Dimitrios Tzachanis, Vassiliki A. Boussiotis, Katarina Luptakova, Jon E. Arnason, Natalie Drummy, Carol Delaney, Emma Breault, Vicki Held, Lina Bisharat, Nancy Giallombardo, Katharine Conway, Jamie Mortellite, Judith Wagoner, Michael Schickler, Rinat Rotem-Yehudar, Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson, Jacob M Rowe, Donald Kufe, David Avigan
Journal: Blood (2012)
Bilateral Involvement Is an Independent Risk Factor in Testicular Relapse of Childhood ALL: Results of the Trials ALL-REZ BFM 83 - 2002
Authors: Christiane Chen-Santel, Ulrike Tabien, Claudia van Schewick, Martin Schrappe, Gabriele Escherich, Angelika Eggert, Günter Henze, Arend Stackelberg, Patrick Hundsdörfer
Journal: Blood (2014)
Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma
Authors: Steven R. Schuster, Klaus Martin Kortuem, Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Laura Bruins, Jessica Schmidt, Gregory Ahmann, Shaji K. Kumar, S. Vincent Rajkumar, Joseph R. Mikhael, Vivek Roy, Betsy R. LaPlant, Kristina Laumann, Bart Barlogie, John D Shaughnessy, Rafael Fonseca, Leif Bergsagel, Martha Q Lacy, Keith Stewart
Journal: Blood (2012)
Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT)
Authors: Thomas Cluzeau, Nathalie Dhedin, Françoise Huguet, Emmanuel Raffoux, Sebastien Maury, Lionel Mannone, Martine Escoffre-Barbe, Ronan Le Calloch, Andre Delannoy, Pascal Turlure, Thorsten Braun, Norbert Vey, Andre Baruchel, Hervé Dombret, Nicolas Boissel
Journal: Blood (2012)
Doctors protest against bill to dissolve the Medical Council of India
Authors: Priyanka Pulla
Journal: BMJ (2016)

Around 270 000 doctors across India took to the streets on 16 November to protest against the newly proposed National Medical Commission bill which seeks to dissolve the Medical Council of India (MCI) and replace it with a body of 20 members who would be nominated by the government.1

K K Aggarwal, the president elect of the Indian Medical Association, told The BMJ that the association was strongly opposed to the idea of a regulatory body with no elected members, and with members from fields other than medicine.2

In March this year a parliamentary …